Structure-activity analysis of the effects of lysophosphatidic acid on platelet aggregation.
Lysophosphatidic acid (1-acyl-sn-glycero-3-phosphate or LPA) is a phospholipid mediator displaying numerous and widespread biological activities and thought to act via G-protein-coupled receptors. Here we have studied the effects on human platelets of a number of LPA analogues, including two enantiomers of both N-palmitoyl-(L)-serine-3-phosphate ((L) and (D)NAPS for N-acyl-phosphoserine) and 2-(R)-N-palmitoyl-norleucinol-1-phosphate ((R) and (S)PNPA), cyclic analogues of 1-acyl-sn-glycero-3-phosphate (cPA) and of 1-O-hexadecyl-sn-glycero-3-phosphate (cAGP), sphingosine-1-phosphate (SPP), as well as two palmitoyl derivatives of dioxazaphosphocanes bearing either a P-H or a P-OH bond (DOXP-H and DOXP-OH, respectively). Nine of these compounds induced platelet aggregation with the following order of potency: SPP < cAGP < DOXP-OH < (L)NAPS = (D)NAPS < (R)PNPA = (S)PNPA < LPA < AGP, EC50 varying between 9.8 nM and 8.3 microM. Two of these compounds (SPP and cAGP) appeared as weak agonists inducing platelet aggregation to only 33% and 41%, respectively, of the maximal response attained with LPA and other analogues. In cross-desensitization experiments, all of these compounds specifically inhibited LPA-induced aggregation, suggesting that they were all acting on the same receptor(s). In contrast, cPA and DOXP-H did not trigger platelet aggregation but instead specifically inhibited the effects of LPA in a concentration-dependent manner. The inhibitory action of cPA did not vary with the acyl chain length or the presence of a double bond and did not involve an increase in cAMP. These data thus confirm the lack of stereospecificity of platelet LPA receptor(s). In addition, since the order of potency of some analogues is different from that described in other cells, our results suggest that platelets contain (a) pharmacologically distinct receptor(s) whose molecular identity still remains to be established. Finally, this unique series of compounds might be used for further characterization of other endogenous or recombinant LPA receptors.
Gueguen
G
G
Institut Fédératif de Recherche en Immunologie Cellulaire et Moléculaire, Université Paul Sabatier, Centre Hospitalo-Universaire de Toulouse, INSERM Unité 326, France.
Gaigé
B
B
Grévy
J M
JM
Rogalle
P
P
Bellan
J
J
Wilson
M
M
Klaébé
A
A
Pont
F
F
Simon
M F
MF
Chap
H
H
D006801:Humans; D008246:Lysophospholipids / Q000819:agonists / Q000037:antagonists & inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D010168:Palmitates / Q000819:agonists / Q000737:chemistry; D010768:Phosphoserine / Q000819:agonists / Q000031:analogs & derivatives / Q000737:chemistry; D010974:Platelet Aggregation / Q000187:drug effects*; D011956:Receptors, Cell Surface / Q000819:agonists / Q000737:chemistry; D043562:Receptors, G-Protein-Coupled; D049368:Receptors, Lysophosphatidic Acid; D013110:Sphingosine / Q000819:agonists / Q000031:analogs & derivatives / Q000737:chemistry; D013329:Structure-Activity Relationship
D008246:Lysophospholipids; C101516:N-palmitoylserine phosphoric acid; D010168:Palmitates; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D049368:Receptors, Lysophosphatidic Acid; C120117:dioxazaphosphocane-H; D010768:Phosphoserine; C026671:1-palmitoyl-lysophosphatidic acid; C060506:sphingosine 1-phosphate; D013110:Sphingosine